Drug-Eluting Stents Unlikely To Dramatically Reduce CABG Demand – ECRI
This article was originally published in The Gray Sheet
Executive Summary
Increased use of drug-eluting stents will not significantly erode the number of coronary artery bypass surgeries (CABG) performed, according to an ECRI technology assessment
You may also be interested in...
MedPAC To Weigh Recalibrating Cardiac DRGs To Improve Payment Accuracy
Cardiac DRG payment accuracy will be evaluated by MedPAC as part of a Congressionally mandated report on physician-owned specialty hospitals
MedPAC To Weigh Recalibrating Cardiac DRGs To Improve Payment Accuracy
Cardiac DRG payment accuracy will be evaluated by MedPAC as part of a Congressionally mandated report on physician-owned specialty hospitals
Drug-Eluting Stents Will Pay Their Own Way According To SIRIUS Cost Study
The additional costs associated with implanting Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent instead of a bare metal stent are almost entirely recouped within the first year post-implant, according to a cost-effectiveness analysis of the SIRIUS trial